EXHIBIT 99.1
RBC Life Sciences, Inc.
2301 Crown Court — Irving, Texas 75038
| | |
| For Immediate Release | | For Further Information: |
| | | Steve Brown, CFO |
| | | Tel: 972-893-4000 |
| | | steveb@rbcls.com |
| | | www.rbclifesciences.com |
RBC Life Sciences Reports Second Quarter Earnings 74 Percent Higher
Irving, Texas (July 31, 2007) — RBC Life Sciences, Inc. (OTC BB: RBCL) today reported a 15 percent increase in net sales to $7,148,000 in the second quarter of 2007 compared to net sales of $6,203,000 in the same period last year. The Company’s net earnings in the second quarter of 2007 increased 74 percent to $510,000, or $0.02 per share, compared to net earnings of $293,000, or $0.01 per share, in the second quarter of 2006.
The Company also reported a 14 percent increase in net sales to $12,540,000 in the first six months of 2007 compared to net sales of $11,011,000 in the same period last year. The Company’s net earnings increased 229 percent to $835,000, or $0.04 per share, in the first six months of this year compared to net earnings of $254,000, or $0.01 per share, in the same period last year.
Clinton Howard, Chairman and CEO of RBC Life Sciences, said, “The significant increase in earnings in the first half of this year was driven by improved operating profits and strong sales in both of our operating segments: nutritional supplements sold under the RBC Life Sciences brand and professional wound care products sold under the MPM Medical brand. Also, comparative earnings for the first six months of last year were lower due to expenses associated with opening an office in Asia in 2006.”
RBC Life Sciences develops, manufactures and markets skin care products and food supplements often found to be low or missing in modern diets. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than twenty five countries to which the products are shipped.
MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers, to nursing homes, hospitals and cancer clinics.
The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
(continued)
